Skip to main content
Clinical Trials/JPRN-jRCTs042230058
JPRN-jRCTs042230058
Recruiting
Phase 2

Evaluating safety and outcomes of midline catheters for cancer patients receiving 5-FU chemotherapy

Taniguchi Hiroya0 sites61 target enrollmentJuly 11, 2023

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Taniguchi Hiroya
Enrollment
61
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 11, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Taniguchi Hiroya

Eligibility Criteria

Inclusion Criteria

  • (1\) Patients with cancer who will receive continuous intravenous 5\-FU infusion for at least 4 days in the hospital.
  • (2\) Patients must be at least 18 years of age (at the time of signing the consent form).
  • (3\) Performance status (PS) of 0 to 1 at the time of enrollment.
  • (4\) Patients who have been fully informed of the study and who have given written consent of their own free will.

Exclusion Criteria

  • (1\) Patients with any of the following complications.
  • 1\) Myocardial infarction
  • 2\) Congestive heart failure
  • 3\) Angina pectoris with subjective symptoms
  • 4\) Arrhythmia with subjective symptoms
  • 5\) Infection of skin or subcutaneous tissue of bilateral upper arms (e.g.cellulitis)
  • 6\) Burns or ulcers on both upper arms
  • (2\)Patients with any of the following conditions.
  • 1\) Median nerve palsy or ulnar nerve palsy
  • 2\) Cerebral infarciton or hemiplegia requiring puncture insertion from the paralyzed side

Outcomes

Primary Outcomes

Not specified

Similar Trials